Skip to main content
Figure 1 | Molecular Medicine

Figure 1

From: Delayed Administration of Pyroglutamate Helix B Surface Peptide (pHBSP), a Novel Nonerythropoietic Analog of Erythropoietin, Attenuates Acute Kidney Injury

Figure 1

Renal and tubular dysfunction in rats treated with pHBSP or EPO after 30 min ischemia and 48 h reperfusion. Serum urea (A), serum creatinine (B), estimated creatinine clearance (C) and fractional excretion of sodium (D) were measured after sham operation (Sham, n = 6) or renal ischemia-reperfusion injury (IRI, n = 11; IRI + pHBSP, n = 11 (10 µg/kg pHBSP administered 6 h into reperfusion)); and IRI + EPO, n = 14 (1,000 IU/kg EPO administered 4 h into reperfusion)). Data are expressed as means ± SEM for n number of observations. P < 0.05 versus IRI.

Back to article page

Molecular Medicine

ISSN: 1528-3658